Innovaderm Bolsters European Presence With Two Newly-Established Operations Hubs (Spain & Poland)
Innovaderm announced today that its strategic European expansion initiative has reached a major milestone with the launch of two key centres of operations in Poland and Spain.
Biotechnology and pharmaceutical companies can officially partner with the CRO’s team of experts in Europe to manage clinical trials in psoriasis, acne, atopic dermatitis and other dermatology indications. This includes adherence to stringent regulatory requirements, patient recruitment, site selection, clinical monitoring and protocol writing.
“To date, we have successfully completed more than 500 clinical trials at 2,900 sites,” says Dave Selkirk, Innovaderm’s Chief Operating Officer. “The presence of two operations hubs in Europe will allow us to go one step further and accelerate the development of promising therapies that have the potential to transform lives. As we look to the future, our goal is to continue supporting innovation in research and the increasing number of patients with skin conditions worldwide.”
“These are exciting times for Innovaderm,” adds Anne Marie Gaulin, Chief Business Officer. “Our highly skilled employees are specialized in dermatology and understand the nuances of deep regional and pan-European requirements. With its site network, medical expertise, and established KOL relationships, Innovaderm’s team in Europe is ready to help customers advance the next generation of dermatology treatments.”
Innovaderm is one of the largest, independent, full-service CROs in the field of dermatology with early to late phase clinical trial capabilities in 30+ indications. For more information, visit our website.
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005090/en/
Contact information
Kathy Giangaspero
Communications Specialist
Innovaderm Research Inc.
kgiangaspero@innovaderm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stefanini Group Announces Major 2026 Investment and Expansion in France During Brazil-France Forum27.11.2025 10:00:00 EET | Press release
Stefanini Group, a global tech consulting company with expertise in digital transformation and artificial intelligence solutions, today announces a significant, multi-faceted commitment to the French market. The company plans a major investment and strategic expansion throughout 2026. The announcement is timed to the participation of Marco Stefanini, Founder and Global CEO of Stefanini Group, in the technology panel at the LIDE Brazil–France Forum, scheduled in Paris for November 26–27, 2025. “France is a crucial hub for the next wave of global digital transformation. Our increased investment here reinforces our AI-First methodology for French enterprises, leveraging cutting-edge technology to accelerate their digital journey and drive a new era of efficiency and innovation,” said Marco Stefanini. The company is aiming to substantially strengthen its presence in France through a dual approach: AI-driven organic growth and targeted acquisition. The CEO's visit will culminate with a priv
Hytera Introduces Smart PoC Radios P50E and P60 at PMRExpo 202527.11.2025 10:00:00 EET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, has officially launched its latest smart Push-to-Talk over Cellular (PoC) radios – the P50E and the P60 – at PMRExpo 2025. This launch marks a significant expansion of Hytera’s PoC portfolio, delivering the company’s most robust and comprehensive range of devices to date, offering a wide spectrum of options to meet the growing demand for PoC solutions across all sectors throughout Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126296378/en/ Hytera unveiled new PoC radios P50E & P60 at PMRExpo 2025. Stay Smart and Safe with the P50E Featuring a compact 0.96-inch screen and a keyboard-free design, the P50E embodies the design philosophy of the P5 Series – Where Reliability Meets Simplicity. With the addition of the P50E, the P5 Series – which also includes the P50 and the P50 Pro – now provides users greater flexibility to align
SFI Health™ Reports Promising Results From a Preliminary Study Evaluating the Impact of Long-Chain Polyunsaturated Fatty Acids on Reading and Writing Skills in Children27.11.2025 09:15:00 EET | Press release
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is proud to announce the publication on Biomedicine of the results of a new study, conducted by the Italian research institute “IRCCS Eugenio Medea” of “La Nostra Famiglia” association, investigating the correlation between long-chain polyunsaturated fatty acids (LCPUFA) and reading and writing abilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126097656/en/ Italian Research Institute "IRCCS Eugenio Medea" of "La Nostra Famiglia". This investigator-initiated trial is part of an ongoing project investigating the efficacy of omega-3 and omega-6 LCPUFA supplementation to enhance the effects of neuropsychological treatment in children diagnosed with developmental dyslexia (DD). LCPUFAs of the omega-3 group, such as EPA and DHA, play essential roles in microglial activity, neuroinflammatory regulation, and synaptic plasticity—pr
WattCycle Unveils 2025 Black Friday Battery Sales with Europe-Wide Savings on LiFePO4 Batteries27.11.2025 08:00:00 EET | Press release
WattCycle today announces the launch of its Europe-wide Black Friday battery deals 2025, offer up to 60% off for LiFePO4 batteries plus an additional 8% discount at checkout with no minimum order value. All EU users are covered by 30 days price protection policy to ensure they secure the best available price during the promotion. Get your Battery Coupon Code: BlackFriday8% Of particular note is the WattCycle 12V 314Ah battery, featured as the most heavily discounted product in the 2025 Black Friday sales. The battery is offered at €489,99 (was €1.299,99), representing a 60% discount. After using the "BlackFriday8%" battery coupon code only €450.79. This battery delivers 4.019Wh of usable energy and engineered with advanced 200A BMS and EV A+ Grade cells rated for 15.000+ cycles, offering a reliable long-term power solution for diverse applications. WattCycle Marine Solution The European boating season underscores the need for dependable, lightweight power. WattCycle 12V 100Ah TM Blueto
JPMorganChase Announces Intention to Build a New Three-Million Sq Ft Landmark Tower in London27.11.2025 08:00:00 EET | Press release
JPMorganChase is proud to announce its intention to build a new three-million square feet tower in London. This transformative project would enable additional capacity for the firm to grow by creating a world-class workplace for up to 12,000employees, further strengthening London’s position as a global financial hub. The plans are subject to a continuing positive business environment in the UK and the receipt of the necessary approvals and agreements at a national and local level. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126040802/en/ Artist's impression: The view from JPMorganChase's Riverside office Serving as the firm’s principal headquarters in the UK and its most significant presence in EMEA, the building would be situated on the Riverside development in Canary Wharf. The plans will provide employees and clients with a first-class working environment against a backdrop of uninterrupted views across the River Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom